Radiation Segmentectomy Efficacious for Unresectable Liver Cancer
All patients had an initial objective response, 90% had a sustained complete response, and few patients had high-grade adverse events.
Hepatocellular Carcinoma
Real-World Data Differ From Trial Data for Some Gastrointestinal Cancer Drugs
Adding nab-paclitaxel to gemcitabine did not appear to improve survival in a real-world cohort.
Aspirin and Statin Combination Therapy Linked to Lower Risk for HCC
Investigators sought to determine the effect of combined therapy with aspirin and statins on the incidence of hepatocellular carcinoma.
Risk of Hepatocellular Carcinoma Recurrence After Hepatectomy Higher in Men Than Women
Researchers conducted a retrospective cohort study to determine the relationship between sex and HCC recurrence after curative hepatectomy.
Perioperative Cemiplimab Shows Clinical Activity Among Patients With Early-Stage Hepatocellular Carcinoma
Investigators assessed the safety and efficacy of neoadjuvant cemiplimab for treatment of patients with early-stage, resectable hepatocellular carcinoma.
Antihistamines May Reduce Risk of Hepatocellular Carcinoma in Patients With Viral Hepatitis
Researchers found a dose-response relationship between antihistamine use and the risk of hepatocellular carcinoma in patients with viral hepatitis.
STRIDE Regimen Extends Survival in Unresectable Hepatocellular Carcinoma
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE Improves Efficacy of Lenvatinib in Advanced Hepatocellular Carcinoma
TACE improved responses and survival outcomes.
Guideline Issued for External Beam RT in Primary Liver Cancers
EBRT is strongly recommended as a potential first-line therapy for patients with HCC confined to the liver who are not candidates for curative therapy.
First-Line Nivolumab Does Not Improve Survival in Advanced Hepatocellular Carcinoma
Overall survival results with nivolumab were similar to results with sorafenib.
- Loading...
Loading...
Next post in Gastrointestinal Cancers
Loading... 
Loading...